| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 27, 2023 5:15 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new t
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple rec
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023. Event: H.C. Wainwright Presentation On-DemandDate: September 11th, 2023Time: 7:00am ETRegistration: Link *Please note that Company presentation
SC 13G/A - Tharimmune, Inc. (0001861657) (Subject)
SC 13G - Tharimmune, Inc. (0001861657) (Subject)
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma (NASDAQ:HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients' lives,
BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company finance, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its or
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K/A - Tharimmune, Inc. (0001861657) (Filer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 38.4% to $0.14 during Friday's pre-market session. The company's market cap stands at $2.8 million. Synaptogenix (NASDAQ:SNPX) stock rose 13.69% to $0.32. The market value of their outstanding shares is at $3.2 million. Hillstream BioPharma (NASDAQ:HILS) stock increased by 13.68% to $0.26. The market value of their outstanding shares is at $4.4 million. SeaStar Medical Holding (NASDAQ:ICU) shares moved upwards by 12.9% to $0.21. The company's market cap stands at $4.0 million. Alpha Teknova (NASDAQ:TKNO) shares increased by 12.23% to $2.11. The market value of their outstanding shares is at $85.9 million. Agile Therapeutics (NASDAQ:A
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 63.8% to $26.16 during Monday's regular session. As of 13:30 EST, Crinetics Pharmaceuticals's stock is trading at a volume of 21.3 million, which is 4355.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion. Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 42.8% to $0.38. As of 13:30 EST, this security is trading at a volume of 98.4 million shares, making up 278.6% of its average full-day volume over the last 100 days. The company's market cap stands at $60.2 million. Akanda (NASDAQ:AKAN) stock rose 30.3% to $0.86. Trading volume for Akanda's st
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)